AKT, also known as protein kinase B and RAC-PK, was first discovered as an oncogene transduced by the acute transforming retrovirus (AKT-8), which is known to cause leukemia in mice. AKT is the major downstream target of phosphatidylinositol 3-kinase (PI3K), which can be activated by receptor tyrosine kinases in response to various growth factors. AKT is a serine/threonine kinase located at the apex of a cascade of signaling pathways. Deregulated AKT signaling is implicated in cancer cell growth, proliferation, and survival. Novel antitumor strategies have now been developed to target AKT and key downstream targets in the clinic.
KeywordsAKT A-443654 Assessment AT13148 AT7867 CCT128930 GSK690693 Predictive biomarkers Therapeutics Fluorescence in situ hybridization (FISH) Phosphatidylinositol 3-kinase (PI3K) Protein kinase B. See AKT
- Lyons J, Grimshaw K, Woodhead S, et al. AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both in vitro and in vivo models exhibiting AKT pathway deregulation. In: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Abstract B251; 2007; 2007.Google Scholar
- Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer. 2010a;10(7):514–23, doi: 10.1038/nrc2870.Google Scholar
- Yap TA, Patnaik A, Fearen I, et al. First-in-class phase I trial of a selective Akt inhibitor, MK2206, evaluating alternate day and once weekly doses in advanced cancer patients with evidence of target modulation and antitumor activity. J Clin Oncol. 2010b;28:15s. suppl; abstr 3009.Google Scholar